RxDoctor Payments Data

Devi Jhaveri, DO

Allergy/ Immunology · Cleveland, OHNPI 1073749834

Payments from drug & device makers

$369,326in general payments, 2019–2025

Across 1,011 payments — averaging $365.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$141K
  • GSK$124K
  • Kedrion S.p.a.$34K
  • Novartis$18K
  • Grifols Therapeutics LLC$15K
  • Octapharma USA, Inc.$11K
  • plus $26K from 39 others
$21,960in research payments, 2019–2025

Across 26 payments — averaging $844.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ADMA Biomanufacturing LLC$22K

What the payments were for

  • Consulting fees$4,8173%
  • Speaking & faculty fees$118,37082%
  • Travel & lodging$1,8041%
  • Food & beverage$18,59613%
  • Education$3780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$831,896
Medicare patients
147
Services billed
15,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab26$102,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$85,668
Dupixent PenDupilumab15$55,263
Spiriva RespimatTiotropium Bromide57$37,930
Breo ElliptaFluticasone/Vilanterol53$27,682
SymbicortBudesonide/Formoterol Fumarate31$14,514
DuleraMometasone/Formoterol30$12,715
Epinephrine38$12,203
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$5,916
Azelastine Hcl197$5,113
Arnuity ElliptaFluticasone Furoate13$5,057
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$3,891
Albuterol Sulfate HfaAlbuterol Sulfate86$2,220
Wixela InhubFluticasone Propion/Salmeterol11$1,235
Montelukast Sodium161$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$124,318$118,407164 claims
Boehringer IngelheimSpiriva Respimat$5,587$37,93057 claims
AstraZenecaSymbicort$140,921$14,51431 claims
MerckDulera$16$12,71530 claims
Hikma Pharmaceuticals USAEpinephrine$22$12,20338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Cleveland

Where these figures come from

Is this you, or does something look wrong? →